Improving the Efficacy of Conventional Therapy by Adding Andrographolide Sulfonate in the Treatment of Severe Hand, Foot, and Mouth Disease: A Randomized Controlled Trial
Table 1
Characteristics for participants with severe HFMD involved in a randomized trial comparing the efficacy of Andrographolide Sulfonate combination therapy with conventional therapy alone.
Characteristic
Conventional therapy group ()
Andrographolide Sulfonate combination therapy group ()
Male, (%)
76 (66.1)
77 (67.5)
Mean age (SD), m
25.7 (12.6)
26.0 (14.2)
Temperature, (%)
≤37.0°C
35 (30.17)
27 (23.68)
37.1–37.5°C
28 (24.14)
31 (27.19)
37.6–38.0°C
24 (20.69)
22 (19.30)
38.1–38.5°C
16 (13.79)
20 (17.54)
38.6–39.0°C
8 (6.90)
10 (8.77)
>39.0°C
5 (4.31)
4 (3.51)
Typical symptom, (%)
Skin or oral mucosa lesions*
112 (96.6)
105 (92.1)
Enterovirus isolated, (%)
EV 71
64 (55.2)
73 (64.0)
Cox A16
5 (4.3)
2 (1.8)
Others
3 (2.6)
3 (2.6)
Unproven
26 (22.4)
27 (23.7)
Height (SD), cm
85.53 (11.9)
82.87 (11.7)
Weight (SD), kg
13.44 (6.6)
13.77 (7.2)
*The skin or oral mucosa lesions varied among the case patients and were papulovesicular or maculopapular without vesicles.
